2 results
Approved WMOCompleted
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Approved WMOWill not start
The study will be performed in 2 parts, Parts A and B. The purpose of the study is to investigate to what extent BN201 is tolerated. It will also be investigated how quickly and to what extent BN201 is absorbed and eliminated from the body (this is…